

ACO Name and Location

Accountable Care Coalition of New Jersey, LLC
4888 Loop Central Drive
Suite 700
Houston, Texas 77081

ACO Primary Contact

<i>Primary Contact Name</i>	Adrienne Opalka
<i>Primary Contact Phone Number</i>	914-281-0827
<i>Primary Contact Email Address</i>	Adrienne.Opalka@UniversalAmerican.com

Organizational Information

ACO participants:

ACO Participants	ACO Participant in Joint Venture (Enter Y or N)
Nikhil Parikh	N
Arthur Nahas	N
Wedad Michael	N
Ocean Internal Medicine Associates PA	N
Subhash Gopal Mehta,Md,Pa	N
Robert G Beitman, Md Pa	N
Nikhil Parikh	N
Infections Limited East, PC	N
Island Medical Associates, PA	N
Medamerica Group	N
Premier Physician Network, LLC	N

ACO governing body:

Member			Member's Voting Power	Membership Type	ACO Participant TIN Legal Business Name/DBA, if Applicable
Last Name	First Name	Title/Position			
Papastamelos	Athanasios	DO, Medical Director, Vice Chair	15%	ACO Participant	Infections Limited East, PC
Parikh	Nikhil	MD, Voting Member	15%	ACO Participant	Nikhil Parikh
Bassett	Shawn	Executive Director, Voting Member, Chair	23%	Other, CHS Representative	N/A
Nahas	Arthur	MD, Voting Member	15%	ACO Participant	Arthur Nahas
Santili	Charlie	Medicare Beneficiary, Voting Member	2%	Medicare Beneficiary	N/A
Sneh	Jain	MD, Voting Member	15%	ACO Participant	Premier Physicians Network LLC
Alexander	Mark	MD, Voting Member	15%	ACO Participant	MedAmerica Group

Key ACO clinical and administrative leadership:

Adrienne Opalka	ACO Executive
Athanasios Papastamelos	Medical Director
Michael Yount	Compliance Officer
Athanasios Papastamelos, D.O.	Quality Assurance/Improvement Officer

Associated committees and committee leadership:

Committee Name	Committee Leader Name and Position
<i>Management</i>	Athanasios Papastamelos, D.O.

Types of ACO participants, or combinations of participants, that formed the ACO:

- Networks of individual practices of ACO professionals

Shared Savings and Losses

Amount of Shared Savings/Losses

- N/A

Shared Savings Distribution

- N/A

Quality Performance Results

Our ACO did not participate in the Shared Savings Program in the previous performance year, therefore this section is not applicable at this time.

Payment Rule Waivers

- No, our ACO does not use the SNF 3-Day Rule Waiver.

Arrangements Disclosed

REQUIRED PUBLIC DISCLOSURE FOR USE OF AN ARRANGEMENT ENTERED INTO UNDER THE ACO PARTICIPATION WAIVER

Accountable Care Coalition of New Jersey, LLC (the “ACO”) participates in the Medicare Shared Savings Program (“MSSP”) under a contract with the Centers for Medicare & Medicaid Services (“CMS”). The Secretary of the Department of Health and Human Services (“HHS”) by and through CMS and the Office of Inspector General, HHS has provided certain waivers of federal fraud and abuse laws deemed necessary by CMS to carry out the MSSP pursuant to a *Final Waivers in Connection with the Shared Savings Program* dated October 29, 2015, as may be amended, including the ACO Participation Waiver (“Participation Waiver”). On December 22, 2017, the Governing Body of ACO after previous discussions authorized, via unanimous written consent, an arrangement with Laboratory Corporation of America Holdings (“LabCorp”) under which LabCorp will collaborate with ACO to provide ACO with laboratory data and test result values for ACO’s assigned beneficiaries, and jointly develop an outreach program to ACO’s providers/suppliers to provide educational services and information concerning. In addition to educational services, ACO will provide ACO providers/suppliers with, among other things, their applicable test result values and an analysis of such laboratory data so they can improve their patients’ care. Finally, LabCorp will provide a grant of funds to allow ACO to defray a portion of the costs to further develop and implement the program, including investment or modification of ACO’s administrative and clinical systems, and otherwise assisting the ACO’s efforts with respect to the MSSP. Consistent with the requirements of the Participation Waiver, after discussing the proposed arrangement with LabCorp, the Board of Directors made a bona fide determination that an arrangement with LabCorp as described below is reasonably related to the purpose of the MSSP and authorized such arrangement. The collaboration is related to the purposes of the MSSP as it augments ACO’s ability to:

- Promote evidence-based medicine and patient engagement;
- Meet the requirements for reporting quality and cost measures coordinating care;
- Establish clinical and administrative systems;
- Meet the clinical integration requirements of the MSSP;
- Evaluate the health needs of ACO’s aligned population;
- Communicate clinical knowledge and evidence based medicine to Medicare beneficiaries; and
- Develop standards for beneficiary access and communication, including beneficiary access to medical records.

Accordingly, ACO entered into this arrangement having determined that it meets all conditions to enable ACO to avail itself of the Participation Waiver.